Obesity portfolio roadmap beyond GLP-1 with preventive bariatric surgery
Quick Overview
| A global pharma player needed to diversify its obesity portfolio beyond reliance on GLP-1 therapies. With intensifying competition, regulatory uncertainty, and the emergence of Preventive Bariatric Surgery as a complementary solution, the client sought a foresight-led roadmap to guide portfolio strategy, mitigate risks, and capture long-term growth opportunities. |  |
Client Success Details
FutureBridge conducted a comprehensive foresight engagement integrating regulatory horizon scanning, competitive benchmarking, and clinical-commercial insights. The objective was to clarify regulatory shifts, assess adjacent opportunities including Preventive Bariatric Surgery, and provide the client with a clear investment pathway for obesity portfolio resilience.
The key questions addressed were:
   FutureBridge integrated foresight model blending payer interviews, regulatory horizon scans, and clinical-commercial evidence grading enabled a 360° view of obesity market adjacencies. This approach brought forward insights often missed in traditional pipeline assessments, particularly around Preventive Bariatric Surgery’s reimbursement trajectory and market scalability. |
|
 |
 |
Engagement Framework:
|
 |
FutureBridge Impact
|
|
|
Business Value Delivered
Through this foresight-led collaboration, FutureBridge empowered the client to:
- De-risk GLP-1 dependency with diversified, adjacent therapies
- Accelerate investment decisions with evidence-backed, regulatory-aligned insights
- Strengthen portfolio resilience across emerging obesity treatment paradigms
- Shape executive strategy for long-term value creation in a complex market landscape
Let’s talk. With EMA’s GLP-1 reclassification and FDA updates on the horizon, now is the time to reassess your obesity strategy. Connect with FutureBridge to uncover adjacencies and build a resilient, forward-looking portfolio.
